Kestra Medical Technologies vs Pulmonx
Kestra Medical Technologies reported revenue of $95 million in fiscal 2026, about the same as Pulmonx's $90 million in fiscal 2025. Kestra Medical Technologies' revenue grew 59.0% in its latest year, and Pulmonx's grew 8.0%. Kestra Medical Technologies had an operating margin of -141.6%, against -59.3% at Pulmonx. Free cash flow was −$117 million at Kestra Medical Technologies and −$33 million at Pulmonx. Their fiscal years end in different months (April 30 and December 31), so the periods don't line up exactly.
Side by side
| Kestra Medical Technologies | Pulmonx | |
|---|---|---|
| Latest fiscal year | FY2026, Apr 30, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $95M | $90M |
| Revenue growth | 59.0% | 8.0% |
| Revenue growth a year, last 5 years | — | 22.6% |
| Gross margin | 51.4% | 74.2% |
| Operating margin | −141.6% | −59.3% |
| Net margin | −138.4% | −59.7% |
| Free cash flow | −$117M | −$33M |
| Free cash flow margin | −122.6% | −36.3% |
| Return on capital | — | −183.3% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 120.4% | 4.0% |
| Last close | $26.63 | $2.74 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $199,800, sold $9.3 million | sold $547,894 |
| Piotroski F-score | 4 of 9 | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Kestra Medical TechnologiesPulmonx
Operating margin
Percent of revenue
Kestra Medical TechnologiesPulmonx
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Kestra Medical TechnologiesPulmonx
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kestra Medical Technologies and Pulmonx pages.